BioNTech Extends Global Reach, Ambition With Kite’s Neoantigen T-Cell Receptor Assets

German Biotech Sets Sights On Cancer Cell Therapies

 
• By Alaric DeArment
map
BioNTech is expanding its global footprint with the purchase of Kite Pharma's neoantigen TCR R&D program and manufacturing plant • Source: Shutterstock

More from Deals

More from Business